search
GLP-1 receptor agonists
Trends
- 1Youth on GLP-1 Weight-Loss Drugs Show Nutritional Deficiencies▼Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.
- 2Oral GLP-1 pill safiglipron shows promise in early type 2 diabetes●Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature reports that safiglipron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The pill-based alternative to injectable GLP-1 drugs is drawing attention as a potentially easier-to-take option for blood sugar control and weight management.